The Linear Team

Anita brings over 25 years of leadership experience in clinical development across the medical device and biopharmaceutical sectors. Her career spans senior roles within Australia’s national science agency, government, and global commercial and clinical-stage companies, where she has successfully driven innovation and research translation programs.

Anita currently serves as Vice President and Deputy Chair of ARCS Australia, the peak industry body for therapeutic development professionals in Australia, and holds board positions with 3Helix, Inc., Indication BioScience , and Kither Biotech. She is also the Founder and Managing Director of Innoveren Pty Ltd, a boutique consultancy focused on research translation and commercialisation. Previously, she served as an Independent Director of the Australian Clinical Trials Alliance.

With deep expertise in governance, compliance, and commercial strategy, Anita’s extensive board experience is matched by her strong track record in clinical trial management, business development, and stakeholder engagement.

Roger is currently the chair of Linear Clinical Research Limited and a non-executive director of CTI Logistics Limited (ASX:CLX), Eagle Mountain Mining (ASX:EM2) and Cullen Wines (Australia) Pty Ltd. He has held a number of non-executive director roles over the past 25 years including in the health and medical research, aged care and education sectors, including as a board member of the Harry Perkins Institute of Medical Research from 2015 to 2024.
Roger was a partner of PricewaterhouseCoopers for 19 years up to his retirement from the firm in 2016. He has extensive experience in financial analysis, company and business valuations, transaction due diligence and mergers and acquisitions across a range of industries and led the PwC Perth Deals team for seven years.
He is a graduate of Macquarie University and a Fellow of Chartered Accountants Australia and New Zealand, a Fellow of the Australian Institute of Company Directors and a former Senior Fellow of the Financial Services Institute of Australia.

Peter is a current Director and the inaugural and Past-Chair of Linear Clinical Research (Linear), a wholly owned subsidiary of the Harry Perkins Institute of Medical Research (Perkins) and has been involved with Linear since its inception.

He is the Chief Executive Officer and Director of the Perkins and a Professor of Medicine at University of Western Australia (UWA). He graduated in medicine from UWA then undertook specialist training in endocrinology at Royal Melbourne Hospital in the 90s. He completed PhD studies at the Walter and Eliza Hall Institute of Medical Research and postdoctoral studies at Harvard Medical School, before returning to Perth.

Peter is internationally recognised for his RNA-based research on hormone-dependent cancers (breast and prostate) and more lately on poor prognostic tumours (liver, head and neck cancer). As Laboratory Head of Cancer Medicine at the Perkins, he and his team are developing microRNA-based therapies for these solid tumours that are being translated to the bedside.

Peter is a Board Member of the national Association of Australian Medical Research Institutes, fellow of the Australian Academy of Health and Medical Sciences, a Graduate of the Australian Institute of Company Directors and co-founder of miReven, a biotech company focused on developing a novel way to treat liver cancer with micro RNA’s. Peter was appointed an Officer of the Order of Australia in the Australia Day 2021 Honours List for distinguished service to medicine, health and medical research as a physician scientist, to professional societies, and to tertiary education.

Mark has held senior executive and board positions, in start-ups and listed and unlisted entities in Australia and the USA, over a 30-year career. Most recently Mark was the worldwide CTO and VP for Corporate Strategy at Hewlett Packard Enterprise.
Prior to Hewlett Packard, Mark was the founder of several successful, venture-backed start-ups that have driven technology disruption and business innovation in varied industries. Mark has also served as a non-executive director at Resolute Mining Limited (ASX:RSG appointed 2017), iCentana (ASX:ICE appointed 2018), as non-executive chairman of Decimal Software (ASX:DSX) and is currently a non-executive director at Land Services WA and Land Services SA.

In her 3-decade career as non-executive director, Fiona has gained experience in many sectors, including Energy and Resources, Utilities, Financial Services and Property. She has been a Chairman, Lead Independent Director and Director of approximately 30 companies in the public, private, not-for-profit and government sectors. Previously Fiona was a partner with KPMG, working with the firm in Perth, San Francisco and Sydney.
Fiona’s leadership in the WA director community saw her elected as State President of the Australian Institute of Company Directors in 2005 – the first woman to hold this position. Her contribution to the economic progress of WA and to the highest standards of corporate governance was recognised in 2016 when she was awarded the AICD WA Gold Medal and in 2021 when she was made a Member of the Order of Australia (AM) for significant service to the finance, investment, resources and not-for-profit sectors.

Nina has over thirty years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of pharmaceutical product development.
Nina is currently the CEO & Managing Director for Dimerix Limited (ASX:DXB), an Australian drug pharmaceutical company focussed on developing products in inflammatory diseases through clinical trials, licensing and commercialisation. Nina was formerly the Commercial Director for Acrux Limited (ASX:ACR), where she has successfully developed and commercialised multiple products globally. Prior to Acrux, Nina was Director of Commercialisation and Intellectual Property for Immuron Limited (ASX:IMC), and previously spent 6 years in new product development with Wyeth Pharmaceuticals in the UK (now part of Pfizer). Nina holds a PhD in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an MBA from RMIT. Nina is also the Non-executive Chair of SYNthesis BioVentures Pty Ltd.

Professor Cheah is a Specialist Physician in Haematology and Pathology who also serves as a clinical researcher at Hollywood Private Hospital and Sir Charles Gairdner Hospitals. Prof Cheah is recognised among the top 20 lymphoma researchers over the last decade globally according to the website Expertscape. His commitment to prioritising access to clinical trials underscores his dedication to advancing medical knowledge. Prof Cheah is a central figure in clinical research, particularly in the domains of lymphoma and chronic lymphocytic leukemia.

In 2018 Professor Cheah founded Blood Cancer Research WA. BCRWA has transformed the treatment of patients living with these disorders since its inception and has attracted outstanding researchers from around the world to work in Perth to deliver cutting edge clinical trials for Western Australian patients.

Driving excellence in clinical trials, ensuring the highest standards of patient care and groundbreaking advancements in oncology.

Dedicated to bridging the gap between effective people and culture strategies for outstanding business performance and fostering a dynamic, inclusive workplace.

Guiding clinical excellence and safety in early-phase trials, transforming pioneering research into patient-centered outcomes.

Passionate about driving innovation, strategic growth, and impactful change to fulfil our mission and make a meaningful difference. Father, start-up founder, and healthcare professional with a love for travel and medical innovation.

Leading the change in innovative cancer research, ensuring operational excellence and transformative patient care through groundbreaking clinical trials.

Leading innovative, high-quality early-phase trials, turning scientific vision into clinical progress with accuracy and care.